Feb 6 (Reuters) - Labcorp LH.N forecast 2025 revenue above Wall Street estimates after reporting fourth-quarter results beat on Thursday, banking on robust demand for its diagnostic tests.
Demand for diagnostic tests has grown in recent quarters as more people, especially older adults, caught up on procedures after the pandemic.
The company expects annual revenue in the range of $13.88 billion to $14.05 billion, above analysts' average estimate of $13.8 billion, according to data compiled by LSEG.
It expects its 2025 adjusted profit to be between $15.60 and $16.40 per share, with its midpoint in line with estimates of $16.02 per share.
Peer Quest Diagnostics DGX.N also beat Wall Street estimates for fourth-quarter profit and revenue last week, helped by a robust appetite for its diagnostic tests.
The company's fourth-quarter sales rose 9.8% to $3.33 billion, beating analysts' average estimate of $3.31 billion.
Sales in its smaller biopharma laboratory services unit, which offers contract research facilities for biopharmaceutical companies, rose 10.4% to $767 million.
On an adjusted basis, Labcorp posted a profit of $3.45 per share in the quarter ended December 31, above estimates of $3.39.
(Reporting by Puyaan Singh in Bengaluru; Editing by Vijay Kishore)
((Puyaan.Singh@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。